Escherichia coli as Next Generation Probiotics

Creative Biolabs is a leading service provider that focuses on live biotherapeutics drug discovery services. We are committed and proud to be part of this rewarding challenge by offering its support to the novel next-generation probiotics (NGPs) development services and pre-clinical drug discovery for our clients. We are proud to partner with you on the journey of bringing novel Escherichia coli (E. coli)-based live biotherapeutics drugs to disease therapy in the clinic.

Introduction to Escherichia coli

E. coli, a key member of family Enterobacteriaceae, is a gram-negative bacterium with a length of 2.0 μm and a diameter of 0.20-1.1 μm that can be found in the most intestines. E. coli is a type of facultative anaerobe that can survive both aerobic and anaerobic conditions. In general, E. coli can produce adenosine triphosphate (ATP) through aerobic respiration in a case with oxygen, but converts to fermentation or anaerobic respiration in the absence of oxygen. Up to now, a wide variety of E. coli strains, including E. coli E22, E. coli UMN026, E. coli SE15, E. coli F11, and E. coli BL21-DE3, have been isolated from different human samples. Several E. coli strains are associated with food poisoning and are the main cause of diarrhea, urinary tract infections, pneumonia, respiratory diseases, as well as other disorders. However, most E. coli strains are harmless and can be considered as probiotic candidates and used for treating various human diseases.

Low-temperature electron micrograph of a cluster of E. coli bacteria, magnified 10,000 times.Fig.1 Low-temperature electron micrograph of a cluster of E. coli bacteria, magnified 10,000 times.

E. coli for Disease Treatment

Currently, the E. coli-based study in disease models plays an important role in developing a new group of live biotherapeutics drugs for treating a range of diseases. In the last few decades, many intense research attempts have been made to develop effective E. coli-based NGPs. As a result, Creative Biolabs provides a wide spectrum of E. coli- targeted NGPs discovery services for the treatment of many human diseases, including but not limited to:

Inflammatory bowel disease (IBD) is a group of autoimmune diseases that can cause long-term chronic inflammation in the intestine. Many studies have indicated that probiotic E. coli Nissle 1917 strain can provide enhanced protective effects on mice models, suggesting its promising role as a perfect NPG candidate and applied in the IBD treatment. Also, recent reports have shown that some E. coli strains have the characteristics of protective immune regulation and intestinal flora regulation.

Ulcerative colitis (UC) is a common chronic relapsing disease that can lead to a continuous inflammation of the colon. Nowadays, the E. coli Nissle 1917 strain has shown health impacts on the host. Therefore, a large number of E. coli Nissle 1917 strain-based NGPs have been generated for treating patients suffering from UC. The data collected from clinical trials have proven that these NGPs are safe and effective in the prevention of relapses in UC patients. They can be regarded as an alternative to conventional drugs, such as mesalazine, for the UC treatment.

In recent years, new research has illustrated that some E. coli strains can be used for the generation of new therapies for human colorectal cancer (CRC). E. coli can induce strong immune and anti-inflammatory responses in the gut through macrophages or dendritic cells (DCs). Moreover, the clinical data have suggested that E. coli based NGPs are also effective in the management of drug side-effects and other complications.

Structure and mechanisms of action of Escherichia coli Nissle 1917 in disease treatment.Fig.2 Structure and mechanisms of action of Escherichia coli Nissle 1917 in disease treatment. (Scaldaferri, 2016)

As an expert in the field of drug discovery, Creative Biolabs is helping our customers with new live biotherapeutics drug discovery services targeting different disease types. Based on our deep analytical capabilities and vast experience in E. coli studies, our client-focused, the integrated team will anticipate challenges, overcome difficulties, and provide custom preclinical studies with numerous assays. We guarantee the finest results for our customers all over the world. For more information, please feel free to contact us or send us an inquiry.

Reference

  1. Scaldaferri, F., et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J Gastroenterol. 2016, 22(24): 5505-5511.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket